ALNY.NASDAQAlnylam Pharmaceuticals, INC

Form 4: Alnylam Pharmaceuticals CMO Pushkal Garg Reports Stock Transactions

Sentiment:

SEC Form 4

📋All filings for Alnylam Pharmaceuticals, INC
🔒Login to Follow

CMO of Alnylam Pharmaceuticals, Pushkal Garg, reports acquisition and disposal of company stock, including sales to cover tax obligations and transactions under a 10b5-1 trading plan.

Summary

  • Pushkal Garg, the CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, reported transactions involving Alnylam common stock.
  • On February 13, 2025, Garg acquired 3,109 shares of common stock related to the vesting of a performance-based stock unit (PSU) granted in 2021.
  • These shares vested due to the company publicly reporting achievement of non-GAAP operating income profitability for a 12-month calendar year, as determined by the Issuer Board of Directors on February 13, 2025.
  • From February 14 to February 18, 2025, Garg sold a total of 2,484 shares at prices ranging from $250.11 to $264.87 per share.
  • These sales were primarily to cover tax withholding obligations and were also executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 11, 2024.
  • Following these transactions, Garg directly owns 11,989 shares, indirectly owns 431 shares through a managed account, and 250 shares through a trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and partially related to tax obligations and a pre-planned trading plan. The vesting of PSUs is a positive sign, but the stock sales offset this.

Positives

  • The vesting of the PSU indicates that Alnylam Pharmaceuticals achieved a performance milestone related to non-GAAP operating income profitability.
  • The reporting person still holds a significant number of shares after the sales.

Industry Context

Insider trading activity is always closely watched in the pharmaceutical industry, especially for companies like Alnylam that are heavily research and development focused. Executive stock transactions can be interpreted in various ways, but are generally scrutinized for signals about company performance and future prospects.

Comparison to Industry Standards

  • Comparing Alnylam to similar biotech companies like Ionis Pharmaceuticals or Arrowhead Pharmaceuticals, executive stock transactions are a common occurrence.
  • However, the specific details, such as the size and frequency of transactions, and the reasons behind them (e.g., tax obligations, pre-planned trading plans), are crucial for proper interpretation.
  • For example, if other executives at Alnylam or comparable companies are also selling shares, it could indicate a broader trend or sentiment within the industry.
  • Conversely, if the transactions are isolated to one executive and are clearly linked to tax obligations or a pre-planned trading plan, the impact on investor sentiment may be minimal.

Stakeholder Impact

  • The stock sales could have a minor negative impact on shareholder sentiment, but the presence of a 10b5-1 plan mitigates this concern.
  • The vesting of PSUs and achievement of profitability goals could positively impact employee morale.

Key Dates

DateDescription
02/24/2021Reporting person was granted a performance-based stock unit (PSU).
09/11/2024Rule 10b5-1 trading plan adopted by the Reporting Person.
02/13/2025Shares issued to reporting person upon vesting of one-quarter of the shares subject to the PSU.
02/13/2025The People, Culture and Compensation Committee of the Issuer Board of Directors determined achievement of non-GAAP operating income profitability.
02/14/2025Sale of 349 shares of common stock at $252.5.
02/14/2025Sale of 386 shares of common stock at $253.37.
02/14/2025Sale of 258 shares of common stock at $254.35.
02/14/2025Sale of 110 shares of common stock at $255.56.
02/14/2025Sale of 126 shares of common stock at $256.29.
02/14/2025Sale of 60 shares of common stock at $257.51.
02/14/2025Sale of 77 shares of common stock at $258.07.
02/14/2025Sale of 27 shares of common stock at $259.72.
02/14/2025Sale of 49 shares of common stock at $260.57.
02/14/2025Sale of 60 shares of common stock at $261.45.
02/14/2025Sale of 27 shares of common stock at $263.33.
02/14/2025Sale of 32 shares of common stock at $264.87.
02/18/2025Sale of 862 shares of common stock at $250.11.
02/18/2025Sale of 306 shares of common stock at $250.73.
02/18/2025Sale of 110 shares of common stock at $251.6.
02/18/2025Sale of 83 shares of common stock at $256.05.
02/18/2025Sale of 107 shares of common stock at $257.99.
02/18/2025Sale of 80 shares of common stock at $259.1.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.